Power and pitfalls of using transgenic mice to optimize therapy for CPVT: A need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders

Heart Rhythm

Volumn 7, Issue 11, 2010, Pages 1683-1685

  Knollmann, Bjrn C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALSEQUESTRIN; FLECAINIDE; PROPRANOLOL; RYANODINE RECEPTOR 2; VERAPAMIL;

ANTIARRHYTHMIC ACTIVITY; CALCIUM TRANSPORT; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL RESEARCH; DRUG POTENTIATION; GENE MUTATION; GENETIC DISORDER; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 78049468503     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2010.07.028     Document Type: Editorial

References (15)

1. G. Katz, A. Khoury, and E. Kurtzwald Optimizing CPVT therapy in calsequestrin-mutant mice Heart Rhythm 7 2010 1676 1682
2. J. Francis, V. Sankar, V.K. Nair, and S.G. Priori Catecholaminergic polymorphic ventricular tachycardia Heart Rhythm 2 2005 550 554
3. B.C. Knollmann, N. Chopra, and T. Hlaing Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia J Clin Invest 116 2006 2510 2520
4. L. Song, R. Alcalai, M. Arad, C.M. Wolf, O. Toka, and D.A. Conner Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia J Clin Invest 117 2007 1814 1823
5. N. Liu, B. Colombi, and M. Memmi Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model Circ Res 99 2006 292 298
6. N. Rizzi, N. Liu, and C. Napolitano Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model Circ Res 103 2008 298 306
7. D. Jiang, R. Wang, and B. Xiao Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death Circ Res 97 2005 1173 1181
8. M. Hayashi, I. Denjoy, and F. Extramiana Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia Circulation 119 2009 2426 2434
9. R. Rosso, J.M. Kalman, and O. Rogowski Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia Heart Rhythm 4 2007 1149 1154
10. C. van der Werf, P.J. Kannankeril, and S. Viskin Flecainide reduces exercise-induced ventricular arrhythmias in CPVT patients Heart Rhythm 7 Suppl 2010 S42
11. H. Watanabe, N. Chopra, and D. Laver Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans Nat Med 15 2009 380 383
12. R. Rosso, J.M. Kalman, and O. Rogowski Long-term effectiveness of beta blocker and calcium channel blocker combination therapy in patients with CPVT Heart Rhythm 7 Suppl 2010 S423
13. F.A. Hilliard, D.S. Steele, and D. Laver Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass J Mol Cell Cardiol 48 2010 293 301
14. S. Nemoto, G. DeFreitas, D.L. Mann, and B.A. Carabello Effects of changes in left ventricular contractility on indexes of contractility in mice Am J Physiol Heart Circ Physiol 283 2002 H2504 H2510
15. B.C. Knollmann, and D.M. Roden A genetic framework for improving arrhythmia therapy Nature 451 2008 929 936